Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02847559 · ClinicalTrials.gov registry record · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
A Phase 2 study of Recurrent Meningioma and Grade III Meningioma, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 8
- Study locations
NCT02847559 is a Phase 2 study of Recurrent Meningioma and Grade III Meningioma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 27 participants, below the 49-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (45% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT02847559, a Phase 2 study of Recurrent Meningioma and Grade III Meningioma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune is also considered investigational because the US FDA has not approved its use for the treatment of meningiomas. Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient's brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed.
Conditions Studied
Interventions
- BIOLOGICAL Bevacizumab
- PROCEDURE Quality-of-Life Assessment
- PROCEDURE Electric Field Therapy
- DEVICE NovoTTF-200A Device
Study Locations (8)
Illinois
- Northwestern University - Chicago
- Northwestern University- Lake Forest Hospital - Lake Forest
- Northwestern Medicine/ Cadence Health - CDH - Winfield
California
- John Wayne Cancer Center at Providence St. John's Health Center - Santa Monica
Florida
- Miami Cancer Institute - Miami
Georgia
- Piedmont Healthcare - Atlanta
North Carolina
- Vidant Medical Center, East Caroling University - Greenville
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02847559
The ClinicalTrials.gov registry entry for NCT02847559 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 49-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (45% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Meningioma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT02847559 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02847559 about?
NCT02847559 is a clinical study titled "Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma". The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use f...
What is the current status of trial NCT02847559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2016-08-01. Estimated completion is 2026-12.
What conditions does trial NCT02847559 study?
This clinical trial studies the following conditions: Recurrent Meningioma, Grade III Meningioma, Grade II Meningioma, Anaplastic (Malignant) Meningioma, Atypical Meningioma.
What interventions are being tested in trial NCT02847559?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), Quality-of-Life Assessment (PROCEDURE), Electric Field Therapy (PROCEDURE), NovoTTF-200A Device (DEVICE).
Who is sponsoring clinical trial NCT02847559?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02847559 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
RECRUITING · Phase 2
-
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
RECRUITING · Phase 2
-
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
RECRUITING · Phase 2
-
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
RECRUITING · NA
-
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
RECRUITING · Phase 1
-
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.